Rhabdomyolysis News and Research

RSS

Rhabdomyolysis (often shortened to simply "rhabdo") is the rapid breakdown (''lysis'') of skeletal muscle (''rhabdomyo'') due to injury to muscle tissue.

High dose of Zocor could lead to muscle injury, warns FDA

The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg.

20 Mar 2010

Winners of NMSIS scholarship award

Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).

10 Mar 2010

Paracetamol reduces damage caused to kidneys following severe muscle injury

The commonly-used painkiller Paracetamol can protect against kidney failure after severe muscle injury, according to research at the University of Essex.

4 Feb 2010

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Taser study finds serious injuries rare after Taser use

An emergency medicine researcher at Wake Forest University Baptist Medical Center has just published the first large, independent study of injuries from conducted electrical weapon (CEW) or Taser use, finding that serious injuries occurred in fewer than 1 percent of 1,201 Taser uses by law enforcement officers.

19 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Do statins cause muscle problems?

A Michigan State University researcher is studying whether the most popular class of cholesterol-lowering drugs may cause muscle problems in users.

11 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Sedative propofol could be fatal

Patients treated for their prolonged seizures with the sedative propofol may be at high risk for complications and even death. New research presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that the use of propofol as an antiepileptic agent in patients with refractory status epilepticus (RSE), prolonged seizures that do not respond to initial treatment, was associated with significant mortality and morbidity.

28 Oct 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Discovery of gene responsible for statin-induced muscle pain

Statins, the popular class of drugs used to lower cholesterol, are among the most commonly prescribed medications in developed countries.

27 Nov 2007

Benefits of statin drugs continue for years

Scientists in the UK have found that the benefits to the heart from taking statin drugs may last for years and are sustained even after the drugs are stopped.

11 Oct 2007

Kidney specialists review plans for disaster response

Hurricane Katrina and other recent disasters have focused attention on the urgent need for planning to provide health services after natural disasters.

23 Jun 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

How low should our cholesterol be and just how safe are statins?

Experts in Sweden are warning that the new U.S. recommendations for lowering cholesterol levels would increase the risk of harmful side effects with no overall reduction in deaths.

4 Jun 2006

Soldiers at risk for heat illnesses

A study reviewing 22 years of data on heat illness hospitalizations and deaths in the U.S. Army indicates soldiers remain at risk for exertional heat illness. While hospitalization rates for heat illnesses have declined over this period, cases of heat stroke have increased.

6 Sep 2005